ERBB2 and neoplasm: Another patient, MBC4, who was diagnosed as HER2 positive of the primary tumour and HER2 CN were 49(pri) and 51(liv) calculated by WGS data, had a 23.37 months PFS(supplemental Table 1) after treatment with trastuzumab.